Pulmonary arterial hypertension, or PAH, is a serious, progressive condition. Before developing a treatment approach, it’s imperative to make the correct diagnosis and consider patient comorbidities. Identifying which WHO Group patients are in is key, but part of the art of treating PAH is understanding that some patients may have overlap between groups. Developing an effective treatment plan is multifactorial, and treatment selection can involve the objective risk stratification score, cardiac functioning on imaging, and shared decision-making, among other considerations. Don’t miss out on expert insights to help you elevate your practice!
New and Emerging PAH Therapies and Approaches: A Mixture of Hope and Complexity
Hear experts discuss new and emerging therapies for PAH and find out why making the right diagnosis is key when determining your treatment approach.
Live
Broadcast
1.00 available credits
Information
June 18, 2025
12:00 PM - 01:00 PM EDT
Virtual
Share
This broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Share
Share
Share this program on:
Details
Presenters
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Vallerie V. McLaughlin, MD
Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan Medical School
Ann Arbor, MIDr. McLaughlin has reported the following relevant financial relationships with ineligible companies during the past 24 months:
Advisor/Consultant: Aerami, Aerovate, Altavant, Apollo Therapeutics, Bayer, CorVista, CVS/Caremark, Gossamer Bio, Janssen, Keros, Merck, United Therapeutics, Vertex
Contracted Researcher: Aerovate, Altavant/Enzyvant, Gossamer Bio, Keros, Janssen, Merck/Acceleron, SoniVieFaculty:
Kelly Chin, MD
Director, Pulmonary Hypertension Clinical Research
Director, Heart Lung Clinic
UT Southwestern Medical Center
Dallas, TXDr. Chin has reported the following relevant financial relationships or relationships with ineligible companies for any amount during the past 24 months:
Contracted Researcher: Gossamer Bio, Janssen, Merck, Untied Therapeutics
Advisor/Consultant: Gossamer Bio, Janssen, Merck, Untied TherapeuticsIoana Preston, MD
Director, Pulmonary Hypertension Center
Dept. of Pulmonary and Critical Care Medicine
Lahey Hospital and Medical Center
Burlington, MADr. Preston has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Contracted Researcher: Acceleron/Merck, Actelion/Janssen, Keros, Liquidia, Respira, United Therapeutics
Advisor/Consultant: Acceleron/Merck, Actelion/Janssen, Aerovate, Gossamer, Keros, Liquidia, Respira, United TherapeuticsReviewers/Content Planners/Authors:
- Cindy Davidson has no relevant relationships to disclose.
- Anita Galdieri, PharmD, has no relevant relationships to disclose.
- Martha Kingman, NP, has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
- Advisor/Consultant: Aerami, Aerovate, Gossamer, Janssen, Liquidia, Merck
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Discuss the importance of getting the correct pulmonary hypertension (PH) diagnosis
- Evaluate the challenges and strategies for using new pulmonary arterial hypertension therapies with shared decision-making
- Examine recent trial results in PH and discuss possible implications
Target Audience
This activity has been designed to meet the educational needs of pulmonologists and cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with pulmonary hypertension (PH).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-053-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until June 18, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.Commercial Support
This activity is supported by an independent educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Details
Presenters
Overview
Pulmonary arterial hypertension, or PAH, is a serious, progressive condition. Before developing a treatment approach, it’s imperative to make the correct diagnosis and consider patient comorbidities. Identifying which WHO Group patients are in is key, but part of the art of treating PAH is understanding that some patients may have overlap between groups. Developing an effective treatment plan is multifactorial, and treatment selection can involve the objective risk stratification score, cardiac functioning on imaging, and shared decision-making, among other considerations. Don’t miss out on expert insights to help you elevate your practice!
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Vallerie V. McLaughlin, MD
Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan Medical School
Ann Arbor, MIDr. McLaughlin has reported the following relevant financial relationships with ineligible companies during the past 24 months:
Advisor/Consultant: Aerami, Aerovate, Altavant, Apollo Therapeutics, Bayer, CorVista, CVS/Caremark, Gossamer Bio, Janssen, Keros, Merck, United Therapeutics, Vertex
Contracted Researcher: Aerovate, Altavant/Enzyvant, Gossamer Bio, Keros, Janssen, Merck/Acceleron, SoniVieFaculty:
Kelly Chin, MD
Director, Pulmonary Hypertension Clinical Research
Director, Heart Lung Clinic
UT Southwestern Medical Center
Dallas, TXDr. Chin has reported the following relevant financial relationships or relationships with ineligible companies for any amount during the past 24 months:
Contracted Researcher: Gossamer Bio, Janssen, Merck, Untied Therapeutics
Advisor/Consultant: Gossamer Bio, Janssen, Merck, Untied TherapeuticsIoana Preston, MD
Director, Pulmonary Hypertension Center
Dept. of Pulmonary and Critical Care Medicine
Lahey Hospital and Medical Center
Burlington, MADr. Preston has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Contracted Researcher: Acceleron/Merck, Actelion/Janssen, Keros, Liquidia, Respira, United Therapeutics
Advisor/Consultant: Acceleron/Merck, Actelion/Janssen, Aerovate, Gossamer, Keros, Liquidia, Respira, United TherapeuticsReviewers/Content Planners/Authors:
- Cindy Davidson has no relevant relationships to disclose.
- Anita Galdieri, PharmD, has no relevant relationships to disclose.
- Martha Kingman, NP, has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
- Advisor/Consultant: Aerami, Aerovate, Gossamer, Janssen, Liquidia, Merck
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Discuss the importance of getting the correct pulmonary hypertension (PH) diagnosis
- Evaluate the challenges and strategies for using new pulmonary arterial hypertension therapies with shared decision-making
- Examine recent trial results in PH and discuss possible implications
Target Audience
This activity has been designed to meet the educational needs of pulmonologists and cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with pulmonary hypertension (PH).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-053-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until June 18, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.Commercial Support
This activity is supported by an independent educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
CME/CE Live BroadcastPulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
June 12, 2025
07:00 PM - 08:00 PM EDT
1.00 credit Learn moreDistinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 program credits
Jaffer Ajani, MD
0.75 program creditsThe Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
0.75 program creditsHarry Yoon, MD
0.75 program creditsStrategies for Navigating First-Line Treatment Selection in Metastatic ESCC
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
MinuteCE®Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
0.75 program creditsHarry Yoon, MD
Jaffer Ajani, MD
0.75 program credits